OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Neuropathic Corneal Pain
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

by admin | 14th March 2023 | News

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY...

Recent Posts

  • OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
  • OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
  • OKYO Pharma Limited Announces Withdrawal of Public Offering
  • OKYO Pharma Announces Public Offering of Ordinary Shares
  • OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Recent Comments

  1. A WordPress Commenter on Hello world!
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023